Your browser doesn't support javascript.
loading
Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study.
Cascone, T; Sacks, R L; Subbiah, I M; Drobnitzky, N; Piha-Paul, S A; Hong, D S; Hess, K R; Amini, B; Bhatt, T; Fu, S; Naing, A; Janku, F; Karp, D; Falchook, G S; Conley, A P; Sherman, S I; Meric-Bernstam, F; Ryan, A J; Heymach, J V; Subbiah, V.
Afiliação
  • Cascone T; Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: tcascone@mdanderson.org.
  • Sacks RL; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Subbiah IM; Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Drobnitzky N; Department of Oncology, Cancer Research UK and Medical Research Council Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK.
  • Piha-Paul SA; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Hong DS; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Hess KR; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Amini B; Department of Musculoskeletal Radiology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Bhatt T; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Fu S; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Naing A; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Janku F; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Karp D; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Falchook GS; Sarah Cannon Research Institute at HealthONE, Denver, USA.
  • Conley AP; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Sherman SI; Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Meric-Bernstam F; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Ryan AJ; Department of Oncology, Cancer Research UK and Medical Research Council Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK.
  • Heymach JV; Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Subbiah V; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: vsubbiah@mdanderson.org.
ESMO Open ; 6(2): 100079, 2021 04.
Article em En | MEDLINE | ID: mdl-33721621
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Everolimo / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Everolimo / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article